Novel biomarkers for cardiovascular risk assessment: Current status and future directions

James Macnamara, Danny J. Eapen, Arshed Quyyumi, Laurence Sperling

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Cardiovascular disease (CVD) is the leading cause of mortality in the modern world. Traditional risk algorithms may miss up to 20% of CVD events. Therefore, there is a need for new cardiac biomarkers. Many fields of research are dedicated to improving cardiac risk prediction, including genomics, transcriptomics and proteomics. To date, even the most promising biomarkers have only demonstrated modest associations and predictive ability. Few have undergone randomized control trials. A number of biomarkers are targets to new therapies aimed to reduce cardiovascular risk. Currently, some of the most promising risk prediction has been demonstrated with panels of multiple biomarkers. This article reviews the current state and future of proteomic biomarkers and aggregate biomarker panels.

Original languageEnglish (US)
Pages (from-to)597-613
Number of pages17
JournalFuture Cardiology
Volume11
Issue number5
DOIs
StatePublished - Sep 2015
Externally publishedYes

Keywords

  • aggregate biomarker panels
  • biomarker
  • CRP
  • fibrinogen
  • Lp(a)
  • Lp-PLA2
  • proteomics
  • troponin

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Novel biomarkers for cardiovascular risk assessment: Current status and future directions'. Together they form a unique fingerprint.

Cite this